Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CW2IP2: Phase I Pilot Study of 11C-M503
NCT06303921Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Feb 2024
- Primary completion
- Feb 2029
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 11C-HY-2-15 in Parkinson's disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), sponsored by University of Pennsylvania. Primary endpoints: Organ Biodistribution or Dosimetry at 4 weeks and PET Uptake of Tracer at 4 weeks. Started Feb 2024; status: recruiting.
02
Drugs
11C-HY-2-15
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT06303921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303921.